Prices delayed by at least 15 minutes | Print
Invesco Markets Ii PLC IVZ S&P WLD HEALTH ESG UCITS ETF ACC (WHCE)
Not yet a customer?
Low cost dealing from £1.50Choose from our range of SIPP, ISA and Dealing accounts
Find out moreOpen
$6.107
Previous close
$6.137
Trade high
$6.107
Income frequency
-
Year low
$5.352
Year high
$6.314
Replication method
Physical Full
Volume
45
Type
ETF
UCITS
Yes
Dividend yield
–
Ongoing charge
0.18
ISIN
IE000L4EH2K5
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Share price
Asset allocation
Top 10 holdings
Holdings 20/08/2025 | % of assets |
---|---|
AbbVie Inc | 11.63 |
Eli Lilly and Co | 9.47 |
AstraZeneca PLC | 5.57 |
Abbott Laboratories | 4.56 |
Merck & Co Inc | 4.44 |
Roche Holding AG | 4.32 |
Gilead Sciences Inc | 3.78 |
Boston Scientific Corp | 3.49 |
Novartis AG Registered Shares | 3.45 |
UnitedHealth Group Inc | 3.41 |
Investment objective
The investment objective of the Fund is to achieve the net total return of the S&P Developed Ex-Korea LargeMidCap ESG Enhanced Health Care Index (the "Reference Index") less fees, expenses and transaction costs.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.
Asset class
ETFMorningstar ratingTM
Morningstar sustainability ratingTM
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.